In Interview, Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing
A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared lung mucus in the animals, regardless of the presence of genetic mutations that promote the development of the disease.
Results of this study were presented by John Taylor, Spyryx’s president and CEO, at the recent Jefferies Cystic Fibrosis Summit in New York, a press release reported. He also provided an update on the ongoing Phase 1 clinical trial evaluating the safety of SPX-101.
“Patients with cystic fibrosis have difficulty clearing mucus from their lungs, leaving them prone to frequent chest infections, which leads to progressive and irreversible damage to their lungs,” Taylor said in an interview with Cystic Fibrosis News Today. “SPX-101 represents the first therapeutic opportunity to leverage a natural, biological mechanism that is important to maintenance of normal mucus clearance.” [FULL STORY]